Colon Cancer
Conditions
Brief summary
It is particularly important that thorough gut cleansing is achieved prior to the colonoscopy for the procedure to be successful. Polyethylene glycol plus electrolyte (PEG+E) solutions are well established as safe and effective agents for gut cleansing and Norgine has successfully developed a low volume (2 litre) PEG+E gut lavage solution. The efficacy and safety of this solution is similar to the standard 4 litre PEG+E, but with improved patient acceptance. Tolerance, acceptability and satisfaction with the cleansing agent plays an important role in subjects' compliance with gut preparation procedure. The study medication NRL0706 is identical to the PEG+E-containing gut lavage solution commonly used in clinical practice, with the exception that the flavour has been modified from lemon to orange. This study is to investigate the tolerability, acceptability, safety and efficacy of a single dose of NRL0706 (MOVIPREP Orange) in subjects without gastrointestinal symptoms undergoing colonoscopy for colon cancer screening.
Interventions
DRUGNRL0706
Patients receive 1 litre of NRL0706 solution followed by 0.5 litre of clear liquid during the afternoon/evening prior to colonoscopy. Patients receive 1 litre of 0706 solution followed by 0.5 litre of clear liquid during the morning of colonoscopy.
Sponsors
Norgine
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* The subject's written informed consent must be obtained prior to inclusion. * Male or female ambulatory subjects aged between 40 to 75 years undergoing a complete colonoscopy for colon cancer screening. * No history of significant gastrointestinal diseases, including gastrointestinal obstruction and perforation or acute symptoms requiring a colonoscopy procedure. * Willing to undergo a colonoscopy for colon cancer screening. * Willing, able and competent to complete the entire procedure and to comply with study instructions. * Females of childbearing potential must employ an adequate method of contraception.
Exclusion criteria
* History of gastric emptying disorders * History of ileus, toxic megacolon, gastrointestinal obstruction and colonic perforation * History of Phenylketonuria * Known Glucose-6-phosphate dehydrogenase deficiency * Known hypersensitivity to macrogol 3350, sodium sulphate or ascorbic acid/ sodium ascorbate * History of colonic resection * Requirement for permanent medication and associated stable serum concentrations (e.g. neuroleptic drugs) * Presence of congestive heart failure (NYHA III + IV) * Acute life-threatening cardiovascular disease * Documented history of severe renal insufficiency * Application of any unlicensed medication within the previous 3 months or participation in any other research study in the last 3 months * Females who are pregnant, nursing or planning a pregnancy. Females of child bearing potential not using reliable methods of contraception * Subjects who the investigator feels would not be compliant with the requirements of the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Acceptance on VAS (100mm) rating | 12 hours |
Secondary
| Measure | Time frame |
|---|---|
| Tolerance on five-point VRS | 12 hours |
| Taste Evaluation on VAS (100mm) rating | 12 hours |
| Acceptability rated by compliance, four-point VRS and VAS (100mm) rating | 12 hours |
| Efficacy on five-grade scale for pre-defined colon areas | 12 hours |
Countries
Germany
Outcome results
None listed